Publications by authors named "Daniel H Petroni"
Background: Peanut allergy is a common, life-threatening food allergy in children. We evaluated whether dupilumab, which blocks the activity of interleukin (IL)-4/IL-13, enhances the efficacy of oral immunotherapy (OIT) AR101 in pediatric patients with peanut allergy.
Methods: A Phase II, multicenter, randomized, double-blind study was conducted in the USA (NCT03682770) in pediatric patients (6-≤ 17 years old) with confirmed peanut allergy.
Background: Patients with idiopathic anaphylaxis (IA) may fail to respond to a combination of high-dose H and H antihistamines and mast cell stabilizers. Treatment options for these patients are currently limited.
Objective: To describe the clinical experience of omalizumab use for the treatment of patients with IA with no evidence of underlying clonal mast cell disorders.
Article Synopsis
- The ARC004 study explored the long-term effects and various dosing regimens of daily oral immunotherapy with Peanut allergen powder (PTAH) in peanut-allergic children and adolescents, following positive results from the PALISADE trial.
- A total of 358 participants, both those who had continued from the PALISADE trial and new participants, underwent different daily or non-daily dosing strategies, with safety and efficacy being assessed.
- Results indicated that daily dosing led to higher desensitization rates with sustained safety, and the immune response continued to show signs of improvement in participants over the course of the study.
Omalizumab for chronic urticaria in children younger than 12 years.
Ann Allergy Asthma Immunol
August 2019
Approach to the evaluation of adverse antibiotic reactions in patients with cystic fibrosis.
Ann Allergy Asthma Immunol
October 2016
Background: Adverse drug reactions (ADRs) to antibiotics in patients with cystic fibrosis (CF) are common and often mislabeled as allergies. The labeling of an antibiotic reaction as an allergy can lead to the use of antibiotics that are less efficacious, are more expensive, or have a greater risk of adverse effects.
Objective: To establish a safe approach for the evaluation of ADRs to antibiotics in patients with CF to help clarify future use of these medications.
Neonatal enterovirus myocarditis is a rare but serious infection that is often an underrecognized cause of cardiovascular collapse. Enterovirus myocarditis in patients with such collapse should be suspected when signs of congestive heart failure and tachyarrhythmia are present. The majority of reported electrical disturbances associated with enterovirus myocarditis are ventricular in origin, but the infection can present as atrial tachyarrhythmia.
View Article and Find Full Text PDFThis article is a review of the scientific literature with respect to fine particulate matter (PM), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, and coronary artery disease (CAD). The association between air pollution and respiratory diseases has been extensively investigated for decades; however, the role of air pollution in exacerbating heart disease has only recently become a focus of attention. It has been shown that for every 10-microg/m(3) increase in fine PM in the air, there appears to be a 2.
View Article and Find Full Text PDF